Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Signoretti

Showing results (201-210 of 257) with videos related to

Pageof 26
Sort By:
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
Nature Communications|November 14, 2025
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programsTreg Grubb, Pooneh Koochaki, Sayed Matar, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2011
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1Wenchu Lin, Jian Cao, Jiayun Liu, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Nature|September 4, 2024
A pathology foundation model for cancer diagnosis and prognosis predictionXiyue Wang, Junhan Zhao, Eliana Marostica, et al.
Nature|February 4, 2011
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progressionZhihu Ding, Chang-Jiun Wu, Gerald C Chu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research SummitToni K Choueiri, Laurence Albiges, Michael B Atkins, et al.
Nature Medicine|May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaDavid A Braun, Yue Hou, Ziad Bakouny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2022
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell CarcinomaMatthew Bootsma, Rana R McKay, Hamid Emamekhoo, et al.
Pageof 26

Showing results (201-210 of 257) with videos related to

Sort By:
Pageof 26
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
Nature Communications|November 14, 2025
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programsTreg Grubb, Pooneh Koochaki, Sayed Matar, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2011
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1Wenchu Lin, Jian Cao, Jiayun Liu, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Nature|September 4, 2024
A pathology foundation model for cancer diagnosis and prognosis predictionXiyue Wang, Junhan Zhao, Eliana Marostica, et al.
Nature|February 4, 2011
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progressionZhihu Ding, Chang-Jiun Wu, Gerald C Chu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research SummitToni K Choueiri, Laurence Albiges, Michael B Atkins, et al.
Nature Medicine|May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaDavid A Braun, Yue Hou, Ziad Bakouny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2022
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell CarcinomaMatthew Bootsma, Rana R McKay, Hamid Emamekhoo, et al.
Pageof 26